Eli Lilly and Company (NYSE:LLY) Shares Acquired by State of Alaska Department of Revenue

State of Alaska Department of Revenue grew its position in Eli Lilly and Company (NYSE:LLY) by 2.5% in the first quarter, HoldingsChannel reports. The institutional investor owned 96,339 shares of the company’s stock after acquiring an additional 2,390 shares during the period. Eli Lilly and Company makes up 0.9% of State of Alaska Department of Revenue’s portfolio, making the stock its 13th biggest holding. State of Alaska Department of Revenue’s holdings in Eli Lilly and Company were worth $79,566,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of LLY. Knightsbridge Asset Management LLC boosted its holdings in Eli Lilly and Company by 1.9% in the fourth quarter. Knightsbridge Asset Management LLC now owns 813 shares of the company’s stock valued at $628,000 after purchasing an additional 15 shares during the period. LS Investment Advisors LLC boosted its holdings in Eli Lilly and Company by 1.7% in the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company’s stock valued at $1,933,000 after purchasing an additional 40 shares during the period. CSM Advisors LLC boosted its holdings in Eli Lilly and Company by 30.6% in the fourth quarter. CSM Advisors LLC now owns 1,045 shares of the company’s stock valued at $807,000 after purchasing an additional 245 shares during the period. Proficio Capital Partners LLC boosted its holdings in Eli Lilly and Company by 30.2% in the fourth quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company’s stock valued at $5,202,000 after purchasing an additional 1,562 shares during the period. Finally, Bfsg LLC boosted its holdings in Eli Lilly and Company by 1.4% in the first quarter. Bfsg LLC now owns 2,959 shares of the company’s stock valued at $2,444,000 after purchasing an additional 42 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $784.28 on Thursday. The business’s 50 day simple moving average is $778.55 and its 200-day simple moving average is $801.58. The firm has a market capitalization of $743.29 billion, a price-to-earnings ratio of 63.81, a price-to-earnings-growth ratio of 1.16 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to analysts’ expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. Eli Lilly and Company’s revenue was up 45.2% compared to the same quarter last year. During the same period last year, the firm earned $2.58 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Friday, May 16th were paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company’s payout ratio is currently 48.82%.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Wall Street Zen upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Saturday, June 7th. HSBC lowered Eli Lilly and Company from a “buy” rating to a “reduce” rating and decreased their target price for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. Guggenheim reaffirmed a “buy” rating on shares of Eli Lilly and Company in a report on Friday, May 23rd. UBS Group decreased their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Finally, Wells Fargo & Company reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.